Northern Trust Corp boosted its stake in shares of Omeros Co. (NASDAQ:OMER) by 2.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 615,377 shares of the biopharmaceutical company’s stock after purchasing an additional 12,827 shares during the quarter. Northern Trust Corp owned approximately 1.27% of Omeros worth $11,162,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of OMER. Russell Investments Group Ltd. increased its holdings in Omeros by 30.8% during the 1st quarter. Russell Investments Group Ltd. now owns 29,884 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 7,037 shares during the period. Principal Financial Group Inc. increased its holdings in Omeros by 10.2% during the 1st quarter. Principal Financial Group Inc. now owns 29,433 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 2,723 shares during the period. Bank of Montreal Can purchased a new stake in Omeros during the 2nd quarter worth about $756,000. Nisa Investment Advisors LLC purchased a new stake in Omeros during the 2nd quarter worth about $1,099,000. Finally, Lesa Sroufe & Co purchased a new stake in Omeros during the 2nd quarter worth about $310,000. Institutional investors own 47.42% of the company’s stock.
OMER has been the subject of several analyst reports. Zacks Investment Research raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th. HC Wainwright set a $34.00 price objective on Omeros and gave the stock a “buy” rating in a research report on Wednesday, July 18th. MED reaffirmed a “reduce” rating on shares of Omeros in a research report on Monday, July 23rd. Maxim Group upped their price objective on Omeros from $25.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 10th. Finally, Wedbush set a $20.00 price objective on Omeros and gave the stock a “hold” rating in a research report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Omeros presently has an average rating of “Hold” and a consensus price target of $27.56.
NASDAQ:OMER opened at $13.02 on Friday. Omeros Co. has a 1 year low of $8.36 and a 1 year high of $27.00.
Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.09). The firm had revenue of $4.61 million during the quarter, compared to analyst estimates of $3.07 million. During the same period in the prior year, the company posted ($0.16) earnings per share. As a group, sell-side analysts predict that Omeros Co. will post -2.48 earnings per share for the current fiscal year.
In related news, VP Marcia S. Kelbon sold 7,529 shares of the company’s stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $25.75, for a total value of $193,871.75. Following the completion of the sale, the vice president now directly owns 227,645 shares of the company’s stock, valued at approximately $5,861,858.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 12.10% of the stock is owned by corporate insiders.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Further Reading: What is a Call Option?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.